ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2391

New Disease Manifestations After Diagnosis in Six Types of Vasculitis

Peter C. Grayson1, David Cuthbertson2, Simon Carette3, Gary S. Hoffman4, Nader A. Khalidi5, Curry L. Koening6, Carol A. Langford7, Kathleen Maksimowicz-McKinnon8, Paul A. Monach9, Philip Seo10, Ulrich Specks11, Steven R. Ytterberg12 and Peter A. Merkel13, 1Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, 2Department of Biostatistics, University of South Florida, Tampa, FL, 3Div of Rheum/E1-422, UHN/MSH, Toronto, ON, Canada, 4Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 5Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 6Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, 7Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 8Rheumatology, University of Pittsburgh, Pittsburgh, PA, 9Rheumatology, Boston University, Boston, MA, 10Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Rheumatology Division, Mayo Clinic, Rochester, MN, 13University of Pennsylvania, Philadelphia, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

   Background/Purpose: The proportion of patients who experience new manifestations of vasculitis after diagnosis is unknown.  Our objectives were to quantify the occurrence of new features of vasculitis after diagnosis in 6 types of vasculitis and to compare patterns of disease activity over time.

   Methods: Standardized data collection on 98 disease manifestations in 6 vasculitides, including granulomatosis with polyangiitis (Wegener’s, GPA), microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS), polyarteritis nodosa (PAN), giant cell arteritis (GCA), and Takayasu’s arteritis (TAK), was performed within a set of multicenter, longitudinal cohorts.  For each form of vasculitis, the frequency of disease-specific manifestations at diagnosis was compared to the cumulative frequency of each manifestation.  The percentage of patients who developed new “severe” manifestations after diagnosis, defined as organ-threatening or life-threatening in the small and medium vessel vasculitides and as ischemic/vascular in the large vessel vasculitides, was described. 

   Results: The number of patients and median length of follow-up (years) for the vasculitides was: GPA 341, 7.2; MPA 26, 3.7; CSS 117, 5.1; PAN 55, 4.3; GCA 191, 2.8; TAK 132, 6.8.  On average, patients with vasculitis experienced 1.3 new disease manifestations after diagnosis (GPA – 1.9, MPA – 1.2, CSS – 1.5, PAN – 1.2, GCA – 0.7, TAK – 1.0).  Depending on the type of vasculitis, at least 1 new disease manifestation occurred after diagnosis in 44%-69% of patients (Figure), most notably in GPA and CSS.  A subset of patients (7-28%) with each type of vasculitis experienced ≥ 3 new manifestations after diagnosis.  The 3 most frequent new manifestations after diagnosis for each type of vasculitis are listed in the Table.  New severe manifestations occurred after diagnosis in GPA – 30%, MPA – 27%, CSS – 23%, PAN – 29%, GCA – 26%, and TAK – 45%.  Mean time from diagnosis to initial flare in disease activity did not significantly differ among those who experienced a new manifestation versus a recurrence of prior disease (1.15 vs 1.18 years, p=0.8).

 

   Conclusion: A majority of patients with vasculitis develop new features of disease after diagnosis, including a substantial number of new, severe manifestations.  New manifestations after diagnosis, although more frequent among the small-vessel vasculitides, are also common in patients with medium- or large-vessel vasculitis.  Patterns of disease recurrence after diagnosis are not related to disease duration.  Ongoing clinical assessment of patients with all types of established vasculitis should remain broad in scope.

 

Three Most Frequent New Manifestations After Diagnosis

Type of Vasculitis

New Manifestation

Granulomatosis with polyangiitis
 (Wegener’s)

Arthralgias (11%)

Rhinitis (9%)

Glomerular disease (9%)

Microscopic polyangiitis

Venous thromboembolic event (12%)

Glomerular disease (11%)

Arthalgias (8%)

Churg-Strauss syndrome

Nasal polyp (10%)

Eosinophilic pulmonary infiltrate (9%)

Purpura (8%)

Polyarteritis nodosa

Motor mononeuritis multiplex (12%)

Arthralgias (12%)

Venous thromboembolic event (10%)

Giant cell arteritis

Polymyalgia rheumatica (11%)

Headache (7%)

Arthralgias (7%)

Takayasu’s arteritis

Upper extremity claudication (14%)

Lightheadedness (8%)

Carotidynia (7%)

 


Disclosure:

P. C. Grayson,
None;

D. Cuthbertson,
None;

S. Carette,
None;

G. S. Hoffman,
None;

N. A. Khalidi,
None;

C. L. Koening,
None;

C. A. Langford,
None;

K. Maksimowicz-McKinnon,
None;

P. A. Monach,
None;

P. Seo,
None;

U. Specks,
None;

S. R. Ytterberg,
None;

P. A. Merkel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-disease-manifestations-after-diagnosis-in-six-types-of-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology